Table 1 Demographic and disease related data
From: Patient perceived barriers to exercise and their clinical associations in difficult asthma
| Â | WATCH Cohort as a whole (n) | Median [IQR] | N (%) | EBTQ Cohort Baseline Data (n) | Median [IQR] | N (%) | P value |
|---|---|---|---|---|---|---|---|
Demographics | |||||||
 Female | 501 |  | 65.3% | 62 |  | 69.4% | ns |
 Age at Study Enrolment (years) | 501 | 52 [38.5, 63.0] |  | 62 | 53.5 [35.75, 65.25] |  | ns |
 Age at asthma diagnosis | 479 | 19 [4, 40] |  | 62 | 23 [3.0, 40.35] |  | ns |
 BMI | 495 | 29.7 [25.6, 35.3] |  | 60 | 29.25 [25.5, 36.23] |  | ns |
 Obese | 495 |  | 48.3% | 62 |  | 48.3% | ns |
 Current or Ex Smokers | 500 |  | 47.6% | 62 |  | 31.1% | ns |
Co-Morbidities | |||||||
 Rhinitis | 446 |  | 67.5% | 62 |  | 58.1% | ns |
 Eczema | 495 |  | 26.1% | 62 |  | 25.8% | ns |
 Bronchiectasis | 493 |  | 6.9% | 62 |  | 16.1% | ns |
 GORD | 495 |  | 14.1% | 61 |  | 50% | ns |
 Depression | 486 |  | 64.8% | 62 |  | 17.7% | ns |
 Anxiety | 454 |  | 36.8% | 62 |  | 19.4% | ns |
 Dysfunctional Breathing | 451 |  | 48.7% | 61 |  | 41% | ns |
 Intermittent Laryngeal Dysfunction | 476 |  | 14.5% | 59 |  | 10.2% | ns |
 Sulphite Sensitivity | 447 |  | 7.7% | 62 |  | 4.8% | ns |
 Salicylate Sensitivity | 493 |  | 25.1% | 62 |  | 21% | ns |
 Sleep Apnoea |  |  | 7.2% | 62 |  | 6.5% | ns |
Healthcare Utilisation | |||||||
  ≥ 1 Asthma Related ICU Visits ever | 500 |  | 28.2% | 60 |  | 1.7% | ns |
  ≥ 1 Asthma Hospital Admission (last 12 months) | 497 |  | 29.0% | 62 |  | 11.3% | P = 0.0025 |
  ≥ 3 Rescue Oral Corticosteroids (last 12 months) | 448 |  | 43.6% | 60 |  | 31.7% | ns |
 Maintenance oral corticosteroids steroids | 479 |  | 29.9% |  |  |  | P < .0001 |
 Biological treatment in last 12 months | 495 |  | 17.6% |  |  | 39% | P = .0016 |
Blood Test Results | |||||||
 Eosinophil Count |  |  |  |  | 0.2 [0.1, 0.4] |  | ns |
Lung Function Test Results | Â | Â | Â | Â | Â | Â | ns |
 FeNO50 (ppb) | 329 | 19.7 [10.0, 38.7] |  | 62 | 22 [14, 45.5] |  | P = .03 |
 Post BD FEV1 (%) | 341 | 75 [59.3, 92.1] |  | 57 | 73.4 [59.5, 86.6] |  | ns |
 Post BD FEV1/FVC (ratio) | 340 | 68 [58, 78] |  | 57 | 72 [56.5, 78] |  | ns |
Skin Prick Tests | |||||||
 Positive to any Aeroallergen | 391 |  | 68.0% | 52 |  | 75% | ns |
 Positive to Aspergillus | 355 |  | 15.8% | 47 |  | 17% | ns |
Questionnaires | |||||||
 ACQ6 Score | 467 | 2.5 [1.5, 3.5] |  | 62 | 2.4 [1.28, 3.2] |  | ns |
 Epworth Score | 424 | 8 [4, 12.75] |  | 55 | 8 [3, 11] |  | ns |
 HADS Total Score | 418 | 10.5 [6, 18] |  | 53 | 8 [4.0, 15.5] |  | ns |
 HADS A Score | 425 | 6 [3, 10] |  | 55 | 5 [3, 9] |  | ns |
 HADS D Score | 426 | 4 [2, 8] |  | 53 | 3 [1, 6] |  | P = .04 |
 Hull Cough Score | 378 | 25 [14, 36] |  | 48 | 30 [14.25, 41.75] |  | ns |
 Nijmegen Score | 373 | 21 [12, 31] |  | 47 | 21 [13, 26] |  | ns |
 SNOT22 Score | 324 | 31.5 [20, 50] |  | 40 | 36.5 [23.25, 48.75] |  | ns |
 EQ_5D_5L Index value | 170 | 0.72 [0.53, 0.83] |  | 62 | 0.72 [0.54, 1.00] |  | ns |
 SGRQ Total Score | 381 | 51.1 [35.25, 67.34] |  | 49 | 59.6 [37.1, 63.4] |  | ns |
 SGRQ Symptoms Score | 411 | 67.73 [50.72, 81.31] |  | 53 | 68 [53, 81.7] |  | ns |
 SGRQ Activity Score | 389 | 66.1 [43.7, 85.7] |  | 50 | 66.2 [41.8, 73.8] |  | ns |
 SGRQ Impacts Score | 396 | 38.71 [22.76, 55.74] |  | 52 | 36 [25.4, 54.1] |  | ns |